Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.

Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.

Eytan M. Stein, MD, discusses how the FDA approval of revumenib could improve survival outcomes in KMT2A-rearranged relapsed/refractory acute leukemia.

Michael A. Postow, MD, discusses the potential role for triplet regimens in melanoma management.

Alison Schram, MD, discusses the FDA approval of zenocutuzumab in non–small cell lung cancer and pancreatic cancer harboring NRG1 fusions.

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the need for continued evaluation of prophylactic treatments like tocilizumab and antimicrobial measures for bispecific T-cell engagers.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique AEs like CRS and the need for well-defined protocols.

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique toxicities.

Combination therapies with neoadjuvant ICIs and chemotherapy followed by an adjuvant ICI are here to stay in resectable non–small cell lung cancer.

Martin H. Voss, MD, discusses the clinical significance of the phase 3 KEYNOTE-564 trial in clear cell renal cell carcinoma.

Martin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.